Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Dec 12:13:996453.
doi: 10.3389/fendo.2022.996453. eCollection 2022.

To sleep or not to sleep: An Italian Control-IQ-uestion

Marta Bassi  1   2 , Marina Francesca Strati  1   2 , Valentina Andreottola  1   2 , Maria Grazia Calevo  3 , Giuseppe d'Annunzio  2 , Mohamad Maghnie  1   2 , Nicola Minuto  2
Affiliations

To sleep or not to sleep: An Italian Control-IQ-uestion

Marta Bassi et al. Front Endocrinol (Lausanne). .

Abstract

Objective: Tandem Control-IQ is an advanced hybrid closed loop (AHCL) system with a Sleep Activity Mode to intensify glycemic control overnight. The aim of the study is to evaluate the effectiveness of using Sleep Mode or not among Tandem Control-IQ users.

Research design and methods: We performed a retrospective Tandem Control-IQ data download for patients followed at IRCCS G. Gaslini Pediatric Diabetes Centre. We divided the patients into group 1 (Sleep Mode users) and group 2 (non-users) and compared their overall glycemic data, particularly during nighttime.

Results: Group 1 (n = 49) does not show better nocturnal glycemic control as expected when compared with group 2 (n = 34). Group 2 shows a nighttime TIR% of 69.50 versus 66.25 (p = 0.20). Only the patients who do not use Sleep Mode and with sensor and automatic mode use ≥90% reached TIR >70% during nighttime, as well as lower nocturnal TAR% (18.80 versus 21.78, p = 0.05).

Conclusions: This is the first study that evaluates the real-life effectiveness of the use of Sleep Mode in young patients with T1D. Control-IQ Sleep Activity Mode may not be as effective in Italian patients as in American patients due to the different habits.

Keywords: AHCL (Advanced Hybrid Closed Loop); CGM (continuous glucose monitoring); TIR (time in range); Type 1 diabetes (T1D); sleep; tandem control-IQ.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Comparison of the percentage of patients divided by categories of nighttime TIR between Sleep Activity Mode users (group 1) and non-users (group 2). The analysis included patients using sensor and automatic mode ≥80% (A) or ≥90% (B).
See this image and copyright information in PMC

References

    1. Diabetes Control and Complications Trial Research Group. Nathan DM, Genuth S, Lachin J, Cleary P, Crofford O, et al. . The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med (1993) 329(14):977–86. doi: 10.1056/NEJM199309303291401 - DOI - PubMed
    1. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, et al. . Diabetes control and complications Trial/Epidemiology of diabetes interventions and complications (DCCT/EDIC) study research group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. . N Engl J Med (2005) 353(25):2643–53. doi: 10.1056/NEJMoa052187 - DOI - PMC - PubMed
    1. Cherubini V, Bonfanti R, Casertano A, De Nitto E, Iannilli A, Lombardo F, et al. . Time in range in children with type 1 diabetes using treatment strategies based on nonautomated insulin delivery systems in the real world. Diabetes Technol Ther (2020) 22(7):509–15. doi: 10.1089/dia.2020.0031 - DOI - PubMed
    1. Commissioner O of the. FDA Approves First Automated Insulin Delivery . Device for Type 1 Diabetes. FDA; (2020). Available at: https://www.fda.gov/news-events/press-announcements/fda-approves-first-a.... (Accessed 2021 Aug 17).
    1. Bergenstal RM, Garg S, Weinzimer SA, Buckingham BA, Bode BW, Tamborlane WV, et al. . Safety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes. JAMA. (2016) 316(13):1407–8. doi: 10.1001/jama.2016.11708 - DOI - PubMed